MAP1LC3A

Across TCGA pan-cancer cohorts, MAP1LC3A RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of MAP1LC3A’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where MAP1LC3A RNA is repressed in tumor relative to normal tissue. In most cancer types MAP1LC3A is over-expressed in tumor, although a few such as THCA and KIRP show the opposite, repressed pattern.

THCA, KIRP, and BLCA are the cancer types where MAP1LC3A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP1LC3A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−2.102	<.001	11	view →
KIRP	Male	III,IV	−2.225	<.001	10	view →
BLCA	All	III,IV	−1.578	<.001	9	view →
LUAD	Male	II,III,IV	−0.967	<.001	9	view →
KIRC	All	II,III,IV	−0.542	<.001	8	view →
HNSC	Female	III,IV	−1.168	.007	6	view →
BRCA	All	II,III,IV	−0.400	<.001	4	view →
PRAD	All	All	−0.511	.001	2	view →
LUSC	All	All	−0.448	<.001	2	view →
COAD	All	All	+0.347	.018	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

MAP1LC3A–THCA

Open the THCA breakdown →